Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria M. Tazdait,

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Meta-analysis study of lymph node staging by 18 F-FDG PET/CT scan in non-small cell lung cancer: Comparison of TB and non-TB endemic regions Chih-Ying.

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children.

Rare cancers of the head and neck area in Europe

Volume 164, Issue 6, Pages (December 2000)

Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit Pim J. van Leeuwen, David Connolly, Anna.

Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1–3 brain metastases: Results.

Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer Philippe O. Gannon, Laurent Lessard, Louis-Mathieu.

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: A randomized double-blind.

Colour contrast in ballistic gelatine

Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma – Results and treatment recommendations.

Scoring to predict the possibility of upgrades to malignancy in atypical ductal hyperplasia diagnosed by an 11-gauge vacuum-assisted biopsy device: An.

Jan Stoehlmacher-Williams, Gerhard Ehninger, Dieter R

Volume 32, Issue 1, Pages (February 2013)

The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: A systematic review and meta-analysis Linda L.D. Zhong, Hai-Yong.

A 45-SNP genetic risk score is increased in early-onset coronary artery disease but independent of familial disease clustering Morten K. Christiansen,

Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients Gene Y. Cho, Lucas.

Anastasia A. Theodosiou, Martin H. Johnson

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Cortical stimulation parameters for functional mapping

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

VMAT radiation-induced nausea and vomiting in adjuvant breast cancer radiotherapy: The incidental effect of low-dose bath exposure G. Lazzari, A. Terlizzi,

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

Targeting T Cell Co-receptors for Cancer Therapy

Volume 10, Issue 5, Pages (November 2005)

Response to Carfilzomib Therapy

Photodynamic Therapy for Early Stage Central Type of Lung Cancer

Measurements of metastatic renal cell tumours as determined by diffusion weighted imaging or computed tomography are in close agreement, a pilot study

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Sequencing of the highly polymorphic STR locus SE33

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer Johan F. Vansteenkiste, MD, PhD, Jean-Luc.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer Charles M. Rudin, MD, PhD,

Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer Katrina Woodford, Vanessa Panettieri, Trieumy Tran Le,

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Contamination when collecting trace evidence—An issue more relevant than ever? Ines Pickrahn, Gabriele Kreindl, Eva Müller, Bettina Dunkelmann, Waltraud.

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

The posterior cerebellum, a new organ at risk?

An interstitial hypothesis for breast cancer related lymphoedema

Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy Rebecca Bütof, Calogero Gumina, Chiara Valentini, Antje.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Dnamatch2: An open source software to carry out large scale database searches of mixtures using qualitative and quantitative models Ø. Bleka, M. Bouzga,

Design, fabrication, and validation of patient-specific electron tissue compensators for postmastectomy radiation therapy Daniel F. Craft, Peter Balter,

Maxim Grymonprez, Vincent Vakaet, Maryam Kavousi, Bruno H. Stricker, M

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Colombian results of the interlaboratory quality control exercise 2015

The clinical significance of indeterminate pulmonary nodules in melanoma patients at baseline and during follow-up chest CT Magdy Soliman, Teresa Petrella,

Journal of Thoracic Oncology

H. Simayijiang, V. Pereira, C. Børsting, N. Morling

P Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients R. Ferrara,

Peter de Boer, Stefano Mandija, Anita M

Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer D. Zylla, M.A. Kuskowski, K. Gupta, P. Gupta

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction.

R. Botman, S. U. Tetar, M. A. Palacios, B. J. Slotman, F. J

Uta Griesenbach, A. Christopher Boyd Journal of Cystic Fibrosis

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

Survival, subsequent therapies, and response.

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune.

Presentation transcript:

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria M. Tazdait, L. Mezquita, J. Lahmar, R. Ferrara, F. Bidault, S. Ammari, C. Balleyguier, D. Planchard, A. Gazzah, J.C. Soria, A. Marabelle, B. Besse, C. Caramella European Journal of Cancer Volume 88, Pages 38-47 (January 2018) DOI: 10.1016/j.ejca.2017.10.017 Copyright © 2017 Elsevier Ltd Terms and Conditions

Fig. 1 Kaplan–Meier overall survival estimates. In pink, conventional stable disease, partial and complete responses (n = 37); in green, true progressors (n = 103) and in orange, atypical responses (n = 20). CR, complete response; PR, partial response; SD, stable disease; atypical, atypical responses. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) European Journal of Cancer 2018 88, 38-47DOI: (10.1016/j.ejca.2017.10.017) Copyright © 2017 Elsevier Ltd Terms and Conditions

Fig. 2 Spider plot of pseudoprogressions (A; N = 8) and dissociated responses (B; N = 12). TP, time point; BL, baseline; Dissociated+, dissociated response with clinical benefit; Dissociated−, dissociated response with clinical benefit. European Journal of Cancer 2018 88, 38-47DOI: (10.1016/j.ejca.2017.10.017) Copyright © 2017 Elsevier Ltd Terms and Conditions

Fig. 3 Representative imaging of two patients experiencing early PsPD. (A) PsPD of carcinomatous lymphangitis, peritoneal carcinomatosis and lung metastasis. (B) PsPD of carcinomatous lymphangitis and lung lesions. European Journal of Cancer 2018 88, 38-47DOI: (10.1016/j.ejca.2017.10.017) Copyright © 2017 Elsevier Ltd Terms and Conditions

Fig. 4 Examples of two patients with dissociated responses. (A) Dissociated responses of adrenal, lung and peritoneal lesions. (B) Dissociated responses of adrenal, lymph node and lung lesions. European Journal of Cancer 2018 88, 38-47DOI: (10.1016/j.ejca.2017.10.017) Copyright © 2017 Elsevier Ltd Terms and Conditions